Preclinical drug development must consider the impact on metastasis

Patricia S. Steeg, Robin L. Anderson, Menashe Bar-Eli, Ann F. Chambers, Suzanne A. Eccles, Kent Hunter, Kazuyuki Itoh, Yibin Kang, Lynn M. Matrisian, Jonathan P. Sleeman, Dan Theodorescu, Erik W. Thompson, Danny R. Welch

Research output: Contribution to journalShort survey

29 Scopus citations
Original languageEnglish (US)
Pages (from-to)4529-4530
Number of pages2
JournalClinical Cancer Research
Volume15
Issue number14
DOIs
StatePublished - Jul 15 2009

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Preclinical drug development must consider the impact on metastasis'. Together they form a unique fingerprint.

  • Cite this

    Steeg, P. S., Anderson, R. L., Bar-Eli, M., Chambers, A. F., Eccles, S. A., Hunter, K., Itoh, K., Kang, Y., Matrisian, L. M., Sleeman, J. P., Theodorescu, D., Thompson, E. W., & Welch, D. R. (2009). Preclinical drug development must consider the impact on metastasis. Clinical Cancer Research, 15(14), 4529-4530. https://doi.org/10.1158/1078-0432.CCR-09-1363